Atlanta, GA — September 3, 2025 — Leads & Copy — GeoVax Labs, Inc. (Nasdaq: GOVX) announced that Chairman and CEO David Dodd will present a company overview and host investor meetings during the H.C. Wainwright 27th Annual Global Investment Conference in New York City, September 8-10, 2025.
The presentation, available via webcast beginning at 7:00 am ET on Monday, September 8, will cover recent progress and upcoming milestones for GeoVax’s pipeline. Key updates will include GEO-MVA, a next-generation Mpox/smallpox vaccine; GEO-CM04S1, a multi-antigen COVID-19 vaccine in Phase 2 trials; and Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors.
The company will also highlight how its MVA platform and U.S.-based continuous cell line manufacturing position GeoVax to address critical gaps in vaccine supply diversification, pandemic readiness, and biosecurity.
Institutional investors interested in attending the conference and scheduling meetings with GeoVax leadership should contact their H.C. Wainwright representative.
Company Contact:
info@geovax.com
678-384-7220
Media Contact:
Jessica Starman
media@geovax.com
Source: GeoVax Labs, Inc.
